S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

FDA Approves Regeneron’s Livsayis for Certain Adults With gMG

A treatment that Regeneron describes as the first approved small interfering RNA therapy for generalized myasthenia gravis has received FDA approval for certain adults with the disorder. The company said Livsayis is also its first approved siRNA therapy and neurology medicine.

FDA Approves Regeneron’s Livsayis for Certain Adults With gMG

Generalized myasthenia gravis is an autoimmune muscular disorder that can cause muscle weakness, difficulty breathing and altered vision, among other symptoms. The Myasthenia Gravis Foundation of America said a 2021 study estimated that 37 out of every 100,000 people in the U.S. have myasthenia gravis.

Livsayis, also known as cemdisiran, is a small interfering RNA therapeutic. Regeneron said it lowers circulating levels of C5 protein, limiting terminal complement activation, which the company described as a key driver of the disease.

According to Regeneron, Livsayis is the first and only approved siRNA therapy for generalized myasthenia gravis. The company also said it is the only FDA-approved treatment for the condition administered subcutaneously four times a year.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!